Abbott Laboratories's Stock Analysis

Abbott Laboratories Expands Board of Directors to Thirteen Members

Abbott Laboratories has appointed Nita Ahuja, M.D. to its Board of Directors, increasing the board size from twelve to thirteen members, effective December 12, 2025. This change reflects the company’s ongoing commitment to enhancing its governance and oversight capabilities.

The company’s by-laws were also amended to outline the processes for shareholder nominations and proposals during annual meetings. Shareholders must adhere to specific notice requirements to propose business or nominate directors, ensuring that the board maintains control over the nomination process and that all shareholder actions are properly documented.

Dec 12, 2025 16:10:48

Abbott Laboratories Announces Blackout Period for Retirement Plans

Abbott Laboratories has announced a Blackout Period affecting its Stock Retirement Plans due to administrative changes, including new recordkeepers and trustees. This period will begin on December 24, 2025, and is expected to end during the week of January 11, 2026. During this time, participants will be unable to make any transactions involving their Plan accounts, including changing contribution rates or diversifying investments in Abbott common shares.

Additionally, directors and executive officers will face trading restrictions on Abbott securities during the Blackout Period, as mandated by the Sarbanes-Oxley Act and Regulation BTR. These restrictions will apply from December 15, 2025, until after the fourth quarter earnings release, and will remain in effect even if the general insider trading policy is lifted. Interested parties can obtain more information about the Blackout Period by contacting Abbott Laboratories directly.

Nov 21, 2025 16:06:09

Abbott to Acquire Exact Sciences for $21 Billion in Cash

Abbott Laboratories has entered into a definitive agreement to acquire Exact Sciences Corporation for $105 per common share, totaling approximately $21 billion. This acquisition aims to enhance Abbott's presence in the cancer diagnostics segment, with Exact Sciences being a leader in early cancer detection and precision oncology. The deal is expected to close in the second quarter of 2026, pending shareholder and regulatory approvals. Following the merger, Exact Sciences will operate as a wholly owned subsidiary of Abbott, contributing to Abbott's diagnostics sales, which will exceed $12 billion annually.

The acquisition is supported by a commitment letter from Morgan Stanley for up to $20 billion in senior unsecured bridge loans. Exact Sciences is projected to generate over $3 billion in revenue this year, with a high teens organic sales growth rate. The merger has been unanimously approved by the boards of both companies, and Abbott plans to hold an investor conference call to discuss the transaction further. Key products from Exact Sciences include Cologuard, Oncotype DX, and Cancerguard, which are significant in the cancer diagnostics market.

Nov 20, 2025 07:37:40

Abbott Laboratories Reports Third Quarter 2025 Financial Results

Abbott Laboratories announced its financial results for the third quarter of 2025, reporting a 6.9% increase in sales on a reported basis and a 5.5% increase on an organic basis. The company achieved a GAAP diluted earnings per share (EPS) of $0.94 and an adjusted diluted EPS of $1.30, which excludes specified items. Year-to-date sales also increased by 6.1% on a reported basis. Abbott reaffirmed its full-year organic sales growth guidance and narrowed the adjusted diluted EPS range to $5.12 to $5.18, indicating expected double-digit growth at the midpoint.

In terms of business segments, worldwide Medical Devices sales increased by 14.8%, with significant growth in Diabetes Care and other areas. Nutrition sales rose by 4.2%, driven by strong growth in Adult Nutrition products. However, Diagnostics sales saw a decrease of 6.6% on a reported basis, largely due to a decline in COVID-19 testing-related sales. Abbott's board declared a quarterly dividend of $0.59 per share, marking the company's 407th consecutive quarterly dividend.

Oct 15, 2025 07:33:48

Abbott Laboratories Reports Second Quarter 2025 Financial Results

Abbott Laboratories reported a 7.4% increase in sales for the second quarter of 2025, amounting to $11.142 billion. The company achieved a GAAP diluted earnings per share (EPS) of $1.01 and an adjusted diluted EPS of $1.26, reflecting double-digit growth compared to the previous year. Notably, the gross margin improved to 52.7%, with an adjusted gross margin of 57.0%, marking a 100 basis point increase. The growth in sales was driven by strong performance in its Medical Devices and Established Pharmaceuticals segments, while Diagnostics sales experienced a decline due to reduced COVID-19 testing-related revenue.

For the first half of 2025, Abbott reported a 5.7% increase in sales, with projections for the full year indicating organic sales growth of 7.5% to 8.0%, excluding COVID-19 testing-related sales. The company also announced plans to develop a new cardiovascular device manufacturing facility in Georgia, expected to be completed by 2028. Abbott declared its 406th consecutive quarterly dividend of $0.59 per share, payable on August 15, 2025, to shareholders of record by July 15, 2025.

Jul 17, 2025 07:34:53

Abbott Reports 4% Sales Growth and 8% EPS Increase

Abbott reported a first-quarter GAAP diluted earnings per share (EPS) of $0.76 and an adjusted diluted EPS of $1.09, reflecting a growth of 11.2% compared to the previous year. The company experienced a 4.0% increase in reported sales and a 6.9% organic sales growth, which rose to 8.3% when excluding COVID-19 testing-related sales. The gross margin also improved, with an adjusted gross margin of 57.1%, showing a 140 basis point increase. Abbott reaffirmed its full-year financial guidance and highlighted recent advancements in its medical technology, including the CE Mark for its Volt™ PFA System and the initiation of a pivotal trial for its Coronary Intravascular Lithotripsy System in the U.S.

Conversely, Abbott's Diagnostics segment faced challenges with a reported sales decline of 7.2% and an organic decrease of 4.9%, largely due to reduced COVID-19 testing-related sales. The company noted that COVID-19 testing sales dropped to $84 million from $204 million in the prior year. Additionally, established pharmaceuticals sales grew only 2.7% on a reported basis, indicating slower performance in that area. The international markets also showed mixed results, with some segments experiencing declines attributed to foreign exchange impacts and volume-based procurement programs in China.

Apr 16, 2025 07:36:02

Abbott Reports $42 Billion in Full-Year 2024 Sales

Abbott's fourth-quarter sales reached $11.0 billion, marking a 7.2% increase from the previous year, with organic sales growth at 10.1% when excluding COVID-19 testing. The company also reported a full-year 2024 sales total of $42.0 billion, up 4.6% from 2023, and achieved the upper end of its guidance for organic sales growth and adjusted earnings per share. The gross margin improved, and Abbott announced over 15 new growth opportunities from its R&D pipeline throughout the year.

However, Abbott faced challenges in its Diagnostics segment, with sales affected by declines in COVID-19 testing-related revenue, which dropped to $176 million in the fourth quarter from $288 million the previous year. Additionally, the company discontinued the ZonePerfect product line in its Nutrition business, impacting sales figures. Despite these setbacks, Abbott projects continued organic sales growth for 2025 in the range of 7.5% to 8.5%.

Jan 22, 2025 07:13:21

Abbott Reports Strong Q3 Growth and Raises EPS Guidance

Abbott's third-quarter results for 2024 show a solid performance with total sales reaching $10.6 billion, marking a 4.9% increase compared to the previous year. The company reported impressive organic sales growth of 8.2%, primarily driven by strong demand in the Medical Devices segment, which saw double-digit growth. Additionally, Abbott has raised its full-year earnings guidance, reflecting confidence in its ongoing business strategies and product innovations, including recent partnerships and new product launches aimed at enhancing healthcare solutions.

Despite some challenges in the Diagnostics sector, particularly due to declining COVID-19 testing sales, Abbott's overall diversified business model remains strong. The company also announced a significant $7 billion share repurchase program and continues to uphold its long-standing tradition of increasing dividends, having done so for 52 consecutive years. These factors contribute to a positive outlook for Abbott, indicating robust operational health and commitment to shareholder returns.

Oct 16, 2024 07:37:36

Abbott Q2 2024: Strong Sales Growth and Raised Guidance

Abbott's Q2 2024 results show $10.4 billion in sales with a 4% growth, led by a 9.3% organic sales increase in Medical Devices. The company raised its full-year EPS guidance. They introduced innovative products like Esprit™ BTK system and obtained FDA clearance for glucose monitoring systems. Abbott's CEO highlighted positive momentum and growth opportunities from R&D. Nutrition and Diagnostics segments saw organic growth. However, Diagnostics sales were impacted by lower COVID-19 testing demand. Overall, Abbott reported a robust performance and optimistic outlook for the future.

Jul 18, 2024 07:37:35

Abbott Q1 2024: Sales Growth and Raised Guidance

Abbott's Q1 2024 results show $10.0 billion in sales, with strong organic growth of 10.8%. The company raised its full-year EPS guidance, expecting $3.25 to $3.40 on a GAAP basis and $4.55 to $4.70 adjusted. New product launches and FDA approvals enhance Abbott's offerings. Despite a decline in COVID-19 testing-related sales, the company's overall performance is positive, with consecutive quarters of double-digit organic sales growth.

Apr 17, 2024 07:36:02